Ginkgo Bioworks Holdings Inc vs Tencent Music Entertainment Group - ADR — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.43 (market cap $505.73M), while Tencent Music Entertainment Group - ADR trades at $8.39 (market cap $16.09B). The key difference: Tencent Music Entertainment Group - ADR is far larger — about 31.8× Ginkgo Bioworks Holdings Inc's market cap, and Tencent Music Entertainment Group - ADR pays a 2.75% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | TME | |
|---|---|---|
Market Cap | $505.73M | $16.09B |
Sector | Health | Media |
52-Week High | $16.14 | $26.36 |
52-Week Low | $5.48 | $8.16 |
Enterprise Value | $607.68M | $14.05B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Tencent Music Entertainment (TME) is trading at $8.38, down 15.35% amid mixed Q2 2026 results that showed revenue growth but profit beat expectations. The stock faces bearish technical signals with oversold RSI conditions, while fundamentals remain strong with 33.6% net margin and attractive valuation at 10.29 P/E. Recent news highlights slowing operational growth and competitive pressures, though institutional activity shows mixed positioning with some funds increasing stakes while others reduce exposure.
TME presents a value opportunity with solid profitability and cash flow generation, but near-term headwinds include intensifying competition, AI-related copyright challenges, and slowing user growth. Analyst consensus leans neutral with 45.8% buy ratings, suggesting cautious optimism for long-term investors willing to navigate current volatility.
Trailing returns across standard periods
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →